- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05674097
Blood Flow Path Reconstruction in Rectal Cancer
September 16, 2025 updated by: Guoqin LIU, Shandong First Medical University
Blood Flow Path Reconstruction in Rectal Cancer After High IMA Ligation Through Preoperative and Postoperative Comparison by Manual Subtraction CTA
A total of 89 patients with distal sigmoid and rectal cancer were referred for observation and underwent MS-CTA between June 2020 and March 2022.
The distribution of the left colic artery (LCA) was classified, and the presence of the accessory middle colic artery (AMCA) was assessed.
Blood flow paths were planned preoperatively based on the classification of LCA branches.
High ligation was performed during standard radical surgery.
Intraoperatively, particular care was taken to preserve the bifurcation of the ascending and descending branches of the LCA.
The planned blood flow paths were then compared with the actual postoperative blood flow paths to validate the previously proposed mechanism.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
89
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250013
- Guoqin LIU
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
39 years to 81 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients with distal sigmoid colon or rectal cancer and they were received routine laparoscopic surgery.
Description
Inclusion Criteria:
- Clinical diagnosis of distal sigmoid colon or rectal cancer
- cTNM stage confirmed as I-III on MRI or CT
- Undergoing laparoscopic anterior resection (LAR)
Exclusion Criteria:
- Arterial phase scanning initiated too early
- Unclear anatomic structure on imaging
- No postoperative enhanced CT
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Six pattens of blood flow and AMCA based on the preoperative observation
Time Frame: 1 hour after the manual subtraction computed tomography angiography (MS-CTA) procedure
|
1 hour after the manual subtraction computed tomography angiography (MS-CTA) procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2020
Primary Completion (Actual)
March 8, 2022
Study Completion (Actual)
March 31, 2022
Study Registration Dates
First Submitted
December 21, 2022
First Submitted That Met QC Criteria
December 21, 2022
First Posted (Actual)
January 6, 2023
Study Record Updates
Last Update Posted (Actual)
September 22, 2025
Last Update Submitted That Met QC Criteria
September 16, 2025
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020GQliu
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
It will be available when our paper is accepted.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.